Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed; the last dose of chemotherapy or radiation therapy must be at least  days prior to study registration; concurrent hormonal therapy will be allowed
Prior malignancy is allowed providing it does not require concurrent therapy\r\n* Exception: active hormonal therapy is allowed
Prior whole gland ablative therapy (i.e. cryoablation or high intensity focused ultrasound [HIFU]) for prostate cancer is allowed; prior focal HIFU or treatment for benign prostatic hypertrophy is allowed
Prior whole gland ablative therapy (i.e. cryoablation or high intensity focused ultrasound [HIFU]) for prostate cancer is not allowed
No prior chemotherapy, radiation therapy, or surgery for this malignancy will be allowed; prior endoscopic procedures for superficial disease (endoscopic mucosal resection, cryotherapy, photodynamic therapy, etc.) will not exclude a patient; prior dilatation is also allowed
Participants who received any lymphoma directed chemotherapy or radiotherapy with the exception of a single dose of intrathecal chemotherapy given at the time of the diagnostic lumbar puncture (spinal tap); patients who received chemotherapy or radiotherapy for Kaposis sarcoma >  years prior to study enrollment are allowed as long as the prior treatment did not include doxorubicin in its non-liposomal form; prior exposure to liposomal doxorubicin is allowed; prior exposure to intrathecal therapy given as prophylaxis within  days is allowed
Prior treatment with systemic chemotherapy for bladder cancer. (Prior intravesical treatment is allowed.)
Asymptomatic untreated brain metastases are allowed; symptomatic metastases that have undergone local therapy with radiation therapy (RT) or surgery and have not required an increase in steroid dose in prior  weeks are allowed; disease that has undergone local therapy is not considered measurable (for treatment phase)
Prior medical therapy is allowed but not required
Meningioma that have resulted from prior radiation therapy are allowed
No prior immunotherapy allowed or prior alkylating agents or prior radiation to the brain
Relapsed or refractory acute promyelocytic leukemia (APL), with no available therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects who have failed arsenic trioxide within the last  months are not allowed.
Subjects with DLBCL, BCLu, HGBCL NOS, or HGBCL with translocations of MYC and BCL and/or BCL, must have had no prior chemotherapy for lymphoma. Steroids for palliation prior to enrollment are allowed.
Prior carboplatin allowed provided greater than  months (mos) have elapsed since last dose of carboplatin
Any major surgery, chemotherapy, or immunotherapy within the last  days (limited palliative radiation is allowed >=  weeks); concurrent hydroxyurea is allowed if less than or equal to  grams daily and on stable dose for >=  days prior to study entry
Prior taxane is allowed (as long as the patient is not experiencing grade >  neuropathy and had no history of disease progression on a taxane therapy within  months prior to study enrollment)
Prior use of hormone contraceptives and replacement therapy is allowed (e.g., estrogen and/or progestin), but must have been discontinued at least  days prior to the study enrollment; vaginal preparations (e.g., Vagifem or Estring) are allowed
Prior use of natalizumab for any reason is not allowed
Prior treatment with ziv-aflibercept is not allowed
For patients with LABC, no prior therapy is allowed
No prior therapies (except for anti-estrogen therapy) are allowed for the treatment of the newly diagnosed metastatic breast cancer; patients are allowed to have had prior chemotherapy for breast cancer in the adjuvant setting for at least  months prior to enrollment into this study; patients with a prior diagnosis of malignancy treated >=  years ago are eligible, provided that they have not received prior nab-paclitaxel as part of their prior treatment regimen, and that they meet all eligibility criteria
Glucocorticoid therapy allowed.
Tumor Treatment Field (TT Fields) therapy allowed.
Prior investigational drugs or interventions for invasive breast cancer treatment within  months before registration are not allowed; prior participation in window-of-opportunity trials without therapeutic intent is allowed if intervention is no more than  weeks in duration
Prior therapy with topoisomerase I inhibitors is allowed
Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational; prior therapy with bisphosphonate is allowed; prior radiation therapy to a solitary plasmacytoma is allowed
Have not used exogenous hormone replacement therapy or oral contraception in the year prior to diagnosis; the use of non-systemic estrogen (such as vaginal estrogen use) is allowed
? days for a prior immunotherapy. No prior therapy with check point inhibitors, costimulatory agonists or immunomodulatory agents is allowed.
Radiation therapy within prior  months (prophylactic radiotherapy to prevent gynecomastia within  weeks prior to randomization is allowed)
Prior radiation therapy (RT) after the initial diagnosis will be allowed; patients with prior RT must be at least  months from the completion of RT (or radiosurgery); prior chemotherapy or molecularly targeted therapy will be allowed; patients with prior chemotherapy must be at least  months from the last dose of chemotherapy or molecularly targeted therapy
Any number of prior chemotherapy or targeted agents including rapamycin analogues are allowed
Patients with up to two prior recurrences are allowed
Patients treated with prior Interleukin- will be allowed to be in this study
Prior radiation therapy is allowed but there should not be overlap with the prior high dose regions unless approved by the protocol directors
Prior immune therapy (e.g. related vaccinia and fowlpox vaccines or antigen-specific peptides) is allowed
Concurrent external beam radiation is not allowed with the exception of palliative radiotherapy to a localized region for pain control (i.e. vertebral disease, pelvis, etc) which IS allowed while on the study protocol \r\n* NOTE: patients may need a CSF flow study at the discretion of the treating principal investigator; if a spinal block is seen by CSF flow study or MRI, it will need local RT prior to treatment
Prior radiation allowed
Prior therapy with etoposide and cyclophosphamide is allowed
In the Phase  part, prior olaratumab/doxorubicin combination therapy in  prior treatment line is allowed.
No prior cytotoxic regimens are allowed for this malignancy. Patients may not have had prior chemotherapy or prior radiation therapy to the ipsilateral breast for this malignancy. Prior bis-phosphonate therapy is allowed
Concomitant Medications\r\n* Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study\r\n* Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months\r\n* Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =<  mg/day is allowed; anticoagulation with therapeutic doses of low molecular weight heparin (LMWH) is allowed in patients who are on a stable dose of LMWH for at least  weeks prior to registration; treatment with warfarin is not allowed; anticoagulation in patients with brain metastases is not permitted\r\n* Chronic concomitant treatment with strong inhibitors of CYPA is not allowed; patients must discontinue the drug at least  days prior to registration on the study\r\n* Chronic concomitant treatment with strong CYPA inducers is not allowed; patients must discontinue the drug at least  days prior to the start of study treatment
No prior genetically modified cell therapy that is still detectable or virotherapy allowed
Any prior chemoradiotherapy is allowed
Patients must discontinue therapies for mCRPC, with the exception of GnRH agent, for  days, with the exception of anti-androgens with which there may be a withdrawal PSA response\r\n* Prior chemotherapy is allowed if no progression of disease on chemotherapy\r\n* Prior treatment with sipuleucel-T, radium-, or PARP inhibitor (e.g. olaparib) is allowed\r\n* Tissue biopsy may be performed during washout period
No prior virotherapy allowed
Prior local radiation therapy would be allowed as long as there is at least one non-irradiated index lesion
Prior treatment with murine and huF is allowed
Prior systemic chemotherapy, immunotherapy, or biological therapy, radiation therapy and/or surgery are allowed; prior use of systemic methotrexate >  month prior to study entry is allowed. Intrathecal methotrexate is allowed prior to and during treatment per investigator discretion.
Allowed prior therapy:\r\n* Newly diagnosed DLBCL and low grade B cell lymphoma: No prior therapy is allowed except steroids equivalent to maximum of prednisone  mg once daily for maximum of seven days prior to registration\r\n* Relapsed/refractory low grade B cell lymphoma (only allowed in phase I): A minimum and maximum of one line of prior non-anthracycline containing therapy is allowed; prior localized radiation therapy is not considered a line\r\n* For patients who have had prior chemotherapy or immunotherapy, at least  weeks must have elapsed between last dose and initial dose of RCHOP-selinexor; for patients treated with radio-immunotherapy, at least  weeks
Additional prior systemic treatments not allowed
Prior chemotherapy allowed, but last dose must have been at least  months prior to enrollment
Participant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for Myelodysplastic Syndrome is allowed except for use of cytarabine.
Note: Treatment with bicalutamide and nilutamide within  weeks prior to enrollment is not allowed; treatment with flutamide within  weeks prior to enrollment is not allowed; treatment with all other gonadotrophin-releasing hormone (GnRH) analogues or antagonists is allowed\r\n* Chemotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* Immunotherapy
Prior treatment\r\n* Phase I: exposure to - prior lines of therapy or no therapeutic options\r\n* Phase II: previously untreated for symptomatic MM\r\n* EXCEPTION: =<  days with pulse steroids or localized radiation therapy, without curative intent, for a myeloma-related complication prior to registration is allowed, as considered necessary by the treating physician
Prior treatment with fosbretabulin is allowed, if not given in combination with everolimus
The following patients are allowed:\r\n* Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, -azacitidine or decitabine\r\n* Any prior chemo therapy must have been completed >=  weeks prior to day  of study treatment and the participant must have recovered to eligibility levels from prior toxicity\r\n* There is no limit for prior chemo regimens\r\n* Patients may have received hematopoietic stem cell transplantation for AML or other diseases\r\n* Hydroxyurea is allowed prior to day  of study treatment for count control and during cycle ; the use of hydroxyurea is not allowed beyond completion of cycle 
Prior interferon or interleukin- therapy is NOT allowed
Prior therapy with hydroxyurea, interferon, anagrelide, ruxolitinib, hypomethylating agents, revlimid, thalidomide, steroids, other JAK inhibitors is allowed; for acute myeloid leukemia (AML) patients who are back in chronic phase myeloproliferative neoplasm (MPN), prior induction therapy is allowed
Prior therapies for metastatic melanoma are allowed, including chemo-, cytokine-, immuno, biological and vaccine-therapy as long as they did not include BRAFi, MEKi; prior ipilimumab or PD- directed therapy will be allowed with a washout period of  weeks and if all autoimmune adverse events have resolved to grade  (except endocrine abnormalities that require continuous replacement)
Previous cranial SRS/whole brain radiation therapy (WBRT) is allowed if >  months prior to single isocenter multi-target (SIMT)
No prior systemic chemotherapy for transitional cell carcinoma of the bladder (prior intravesical therapy is allowed); any other prior chemotherapy must have been completed >  years prior to initiation of therapy
Patients with a history of central nervous system metastasis are allowed provided they have been treated (i.e., surgery, radiation, and/or radiosurgery) at least  weeks prior to registration and have stable neurologic function, including no requirement for medication(s) to control symptoms for at least  weeks; patients with known leptomeningeal disease are not eligible; NOTE: Stable low dose dexamethasone allowed at discretion of protocol chair
Prior chemotherapy or other systemic anticancer therapy within  weeks prior to start of olaparib treatment,  weeks for nitrosoureas or mitomycin. Exceptions include: Anti-hormonal treatment for ER positive or PR positive breast cancer is allowed until  days prior to treatment with olaparib, exposure to an investigational agent within  days or  half-lives (whichever is the longer) prior to start of olaparib treatment is not allowed, prior receipt of biologics targeting T cell co-regulatory proteins and/or immune checkpoints is not allowed. Examples include MEDI or other PD or PD-L or PD-L inhibitors or anti-CTLA therapy, previous treatment with a PARP inhibitor, is not allowed.
Patients must have received at least one prior platinum-based chemotherapy for locally advanced or metastatic disease; prior bevacizumab as st line and/or maintenance therapy is allowed; prior nivolumab is allowed
Prior treatment:\r\n* No prior liver radiation therapy or immunotherapy for cholangiocarcinoma\r\n* Only one previous single agent chemotherapy for ICC allowed\r\n* Patient may have prior liver resection
Maintenance therapy during the first platinum-free interval is allowed; however, the last dose must have been at least  days prior to Randomization. No cancer vaccine therapy is allowed.
Patients are allowed to receive, but are not required to receive, up to  additional prior chemotherapy treatment regimens (including platinum-based chemotherapy); prior hormonal therapy is allowed, does not count towards this prior regimen requirement, and must be discontinued at least one week prior to T cell infusion; continuation of hormone replacement therapy is permitted
Previous treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least  year prior to enrollment\r\n* No prior talimogene laherparepvec or tumor vaccines allowed\r\n* No prior radiation to the same tumor bed allowed
Patients whose primary therapy was changed due to suboptimal response or toxicity will be eligible, however no more than  regimens will be allowed prior to ASCT
There is no restriction on the number of prior therapies allowed for this disease and prior radiation and chemotherapy is allowed, provided the subject has recovered from all grade  or greater toxicity prior to enrollment
Prior systemic therapy is allowed, although appropriate washout is required for patients who have been on BRAF inhibitors (at least  days)
History of prior radiation therapy to brain or skeleton is allowed, but should have occurred >  months from enrollment
No recent treatment for thyroid cancer as defined as:\r\n* No prior RAI therapy is allowed <  months prior to initiation of therapy on this protocol; a diagnostic study using <  millicurie (mCi) of RAI is not considered RAI therapy\r\n* No external beam radiation therapy <  weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)\r\n* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed <  weeks prior to the initiation of therapy on this protocol
Patients with higher risk MDS (International Prognostic Scoring System [IPSS] int- or high; or >= % blasts as defined by World Health Organization [WHO])\r\n* No prior intensive chemotherapy or high-dose cytarabine (>=  g/m^)\r\n* Prior biologic therapies (=<  cycle of prior decitabine or azacitidine), targeted therapies, or single agent chemotherapy is allowed\r\n* Off chemotherapy for  weeks prior to entering this study with no toxic effects of that therapy, unless there is evidence of rapidly progressive disease\r\n* Hydroxyurea is permitted for control of counts prior to treatment\r\n* Hematopoietic growth factors are allowed
All prior therapy must have been completed at least  days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least  days prior to enrollment ( weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
Patients who have been treated with vemurafenib will be allowed in this study
Dasatinib use prior to ASCT is allowed
The use of anti-convulsants is allowed, as long as the patient is on a stable dose with no seizure activity for at least  weeks prior to initiating trial therapy
No prior radiation therapy for retroperitoneal sarcoma is allowed
Participants may have had any extent of prior surgery and/or chemotherapy; no prior cranial radiation therapy is allowed
Patients with loss of normal vertebral height, due to for example compression fracture or other process, prior to treatment are not allowed; patients with normal height and compression fracture are allowed
Patients with any other prior malignancy are not allowed except for the following:
Prior cytotoxic therapies are NOT allowed; the only exception is prior corticosteroid therapy (prednisone up to  mg/kg for =<  months) which must be stopped at least  week prior to study enrollment
Prior anti-leukemia therapy within the  days prior to randomization. Prior use of quizartinib or gilteritinib must be discontinued  days prior to randomization. Prior use of hydroxyurea or other palliative treatment for leukocytosis is allowed.
Concurrent malignancy or malignancy within  years prior to starting study drug, with the exception of malignancies that have completed therapy and are considered by their physician to be at less than % risk of relapse; prior systemic therapy is allowed with the exception of prior eribulin; prior radiation therapy is allowed with the exception of any abdominal, pelvic or retroperitoneal radiation >  Gy
Prior chemotherapy or immunotherapy for metastatic urothelial cancer; prior neoadjuvant or adjuvant chemotherapy with first progression >  months is allowed; prior intravesical treatments such as Bacillus Calmette-Guerin (BCG) are allowed, however no BCG is allowed within  weeks prior to initiation of study treatment
NOTE: Patients proceeding to transplant are allowed up to one cycle of consolidation treatment
No prior cancer chemotherapy allowed
Prior systemic therapy directed at advanced RCC is not allowed for patients enrolled to the expansion cohort, treatment naive arm; if prior (neo)adjuvant treatment given as part of a clinical trial, this would be allowed as long as last dose was >  year prior to start of treatment
Up to  prior relapses allowed
Prior therapy requirements:\r\n* Prior radiation, chemotherapy or biologics NOT allowed
No prior chemotherapy or radiation therapy is allowed; patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery
Patients who have had prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX); prior radiation is allowed; chemotherapy for non-metastatic disease is allowed
Prior treatment with Xofigo (Radium), Provenge, mitoxantrone and cabazitaxel is allowed
Prior DLI is allowed, however not within the  days before the st dose of ALT-
Patients are allowed to have up to  prior treatments
Prior use of pazopanib (prior use of other kinase inhibitors allowed)
Prior chemotherapy, and/or radiation therapy is allowed if it has been at least  years or longer since those therapies were given from the time of registration, with the exception of previous pelvic radiation which is NOT allowed under any circumstances
Never treated with cytoreductive drugs except hydroxyurea for up to  months maximum (phlebotomy, aspirin allowed, anagrelide allowed)
Prior therapy:\r\n* No limit to prior therapies with last anti-cancer treatment >=  weeks from initiation of protocol-based therapy provided all toxicities (other than alopecia) have resolved to =< grade  or baseline; for lapatinib and intravenous (IV) trastuzumab and/or pertuzumab, no washout is required\r\n* Patients with prior whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) are eligible, provided that there are new lesions not previously treated by SRS and >=  weeks have passed since radiation\r\n* Patients with prior cranial surgery are eligible, provided that there is evidence of residual disease and/or progression of disease and >=  weeks have passed since surgery\r\n* Prior hormonal therapy for locally advanced or metastatic disease is allowed and can be continued, if everolimus is used in a combination with hormonal therapy, then, everolimus must be discontinued but hormonal therapy can be continued\r\n* Continuation of intravenous (IV) trastuzumab is allowed for those patients already on IV trastuzumab therapy, patients previously treated with intrathecal (IT) trastuzumab are allowed if there is evidence of progression as determined by treating physician and last dose administered is >=  weeks\r\n* Prior capecitabine therapy is allowed, provided >=  months have passed since the last dose of capecitabine
Subjects may have had any number of prior chemotherapy, endocrine therapy, immunologic, or biologic regimens for metastatic breast cancer; treatment with prior platinum compounds (except cisplatin) is allowed as long as it has been  months or more since exposure to prior platinum; prior cisplatin treatment is allowed IF it was given in the adjuvant setting
Prior systemic chemotherapy (prior intravesical therapy is allowed)
Patients must not have received any treatment after discontinuing MEDI with the following exceptions; localized palliative radiation therapy is allowed for symptom management, provided and treatment is completed >=  days prior to RE-TREATMENT registration; local treatment for brain metastases is allowed
Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs.
Prior fenretinide oral capsules is allowed; please consult study chair if prior history of intravenous fenretinide emulsion (allowable if drug stopped due to hypertriglyceridemia); prior -cis, -cis or all-trans retinoic acid are allowed
Prior single modality radiation therapy is allowed
Prior systemic chemotherapy (prior intravesical therapy is allowed)
Prior progesterone treatment for either diagnosis is ALLOWED
Prior treatment with letrozole is allowed if the patient meets the washout period of  days.
Prior chemotherapy, radiation therapy, concurrent chemoradiation are allowed if used for treatment of non-metastatic disease
Prior radiation is allowed
No recent treatment for thyroid cancer as defined as: \r\n* No prior I therapy is allowed <  months prior to initiation of therapy on this protocol; a diagnostic study using <  mCi of I is not considered I therapy\r\n* No external beam radiation therapy <  weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol) \r\n* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed <  weeks prior to the initiation of therapy on this protocol
Subjects must not have had prior surgery (biopsy allowed) or radiation therapy within  months of enrollment.
Prior or concomitant use of megestrol acetate for the treatment of hot flashes is allowed
COHORT A: Prior use of a  alpha reductase inhibitor is allowed (no limit on duration of use); however a two week washout is required
COHORT B: Prior use of a  alpha reductase inhibitor is allowed (no limit on duration of use); however a two week washout is required
For phase II, up to  prior chemotherapy-based treatments are allowed; patients must have had prior trastuzumab-based therapy; prior neratinib treatment is not permitted; prior capecitabine is allowed, if not combined with neratinib
No treatment with any of the following for prostate cancer within  weeks prior to enrollment:\r\n* Hormonal therapy (e.g., androgen receptor [AR] antagonists,  alpha reductase inhibitors, estrogens); Note: treatment with bicalutamide and nilutamide within  weeks prior to enrollment is not allowed; treatment with flutamide within  weeks prior to enrollment is not allowed; treatment with all other gonadotropin-releasing hormone (GnRH) analogues or antagonists is allowed\r\n* Chemotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* Immunotherapy
Prior chemotherapy is allowed
Patients with active biliary obstruction; NOTE: patients for which a shunt has been in place for at least  days prior to the first dose of dabrafenib are allowed
Prior oophorectomy for cancer prevention is allowed
Prior treatment with Gliadel wafer is allowed if it has been at least  months from placement
Prior treatment with letrozole is allowed
Patients whose primary therapy was changed due to suboptimal response of toxicity will be eligible, however no more than  regimens will be allowed prior to ASCT
Prior chemotherapy (unless allowed for some study arms)
Prior adjuvant therapy for CRC including fluoropyrimidines either alone or in combination with oxaliplatin is allowed, provided that all therapy was completed >=  months from cancer recurrence, therapy duration was =<  months, and all prior toxicities have completely resolved (residual grade  neuropathy is allowed)
Dasatinib use prior to ASCT is allowed
Long term concurrent medications and/or treatments Not Allowed: \r\n* Corticosteroids, chemotherapy, cyclosporin A; short term (approximately  week) use of topical, low-dose or inhaled steroids may be allowed at the discretion of the investigator; injectables not allowed
Prior systemic chemotherapy (prior intravesical therapy is allowed)
Prior therapy:\r\n* Prior trastuzumab is allowed for all cohorts\r\n* Prior capecitabine is NOT allowed for participants enrolled to cohorts a/b\r\n* Prior lapatinib is allowed for cohorts , , b but NOT cohort a\r\n* No prior therapy with neratinib is allowed\r\n* There is no limit to the number of previous lines of therapy (including chemotherapy, trastuzumab, and endocrine therapies) at least  weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry\r\n* No washout is required for hormonal therapy but concurrent hormonal therapy is not allowed for patients on study; the only exception to this is longstanding ovarian suppression in pre-menopausal patients, if this has been started >=  months prior to study enrollment; other hormonal therapies are not allowed while patients are on study
Prior adjuvant therapy with an AI and/or tamoxifen is allowed, provided treatment ended at least  weeks prior to the first dose of MEDI-
Prior Navelbine allowed provided Navelbine therapy discontinued >=  months from day  of treatment under this protocol
Prior treatment with lapatinib or trastuzumab are allowed, provided that the agents have never been given in combination
Any number of prior cancer treatments, including investigational agents, chemotherapy, hormone therapy, or targeted therapy are allowed
Prior treatment\r\n* Currently receiving first-line treatment with pemetrexed + platinum; patients are to be registered to Cancer and Leukemia Group B (CALGB)  no later than the last day of cycle  of first line therapy\r\n* Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) are acceptable; prior intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy\r\n* Prior surgical treatment is allowed\r\n* Prior radiation therapy is allowed
For patients who are Her positive and will be treated on the trastuzumab + mDCF cohort, prior trastuzumab treatment is not allowed
Use of raloxifene for bone health is allowed
Prior use of bendamustine for indolent lymphoma allowed if >  years, CR to bendamustine and well tolerated with no residual > grade  toxicity; no prior use of bendamustine for aggressive lymphoma allowed
Prior radiotherapy is allowed if it was given for low-grade lymphoma before transformation in those with transformed NHL and as long as no chemotherapy was administered in conjunction with radiation
For Phase II: Any prior systemic therapy for locally advanced or metastatic melanoma; prior local therapy such as radiation or intratumoral injection is allowed; previous systemic treatment for any stage III disease that was subsequently rendered NED (no evidence of disease) by surgery is allowed
Prior systemic chemotherapy (prior intravesical therapy is allowed)
Prior treatment for pre-existing hematologic conditions is allowed and includes hydroxyurea, thalidomide, hematopoietic growth factors, Zarnestra, lenalidomide, arsenic trioxide, imatinib, corticosteroids, histone deacetylase inhibitors, azacytidine, midostaurin sorafenib or other targeted agents; use of hydroxyurea for control of blast counts is allowed during the trial
For Phase Ib, prior cetuximab or other EGFR-targeted antibody therapy is allowed regardless of the prior treatment settings.
Other CHOP variants: substitution allowed for  component with a drug of the same mechanism of action. Additional components, except alemtuzumab, are allowed. Rituximab may be added if not given within  cycles of randomization.
Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:
Prior treatment with bicalutamide will not be allowed
Prior treatment with interferon alfa is allowed
There are no limits on prior therapy; patients are allowed to have prior chemotherapy and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy or surgery after radiation treatment
Prior therapy with radium- is allowed
Received regional hepatic infusion therapy within  months of enrollment (RFA allowed > months prior to enrollment)
Any number of prior lines of systemic anti-neoplastic therapy are allowed; treatment with =<  prior VEGF inhibitor will be allowed
Prior chemotherapy or radiation therapy for this disease (laser and cryotherapy are allowed and are not considered exclusion criteria)
Prior treatment with Gliadel wafer is allowed if it has been at least  months from placement
For participants who present with de novo metastatic disease, no prior systemic chemotherapy is allowed
Patients must be chemo-nave, i.e., not have received any prior induction chemotherapy for AML or myelodysplastic syndrome (MDS); temporary prior measures such as apheresis or hydroxyurea are allowed; prior anthracycline therapy is allowed, but must not exceed a dose of  mg/m^ daunorubicin or equivalent; prior all-trans retinoic acid (ATRA) for suspected APL is allowed; prior methotrexate for central nervous system (CNS) involvement is allowed; patients with prior history of MDS must not have received azacitidine, decitabine, lenalidomide or vorinostat
Prior malignancy is allowed providing it does not require concurrent therapy; exception: active hormonal therapy is allowed
Prior treatment for MM (prior radiation therapy or dexamethasone up to  mg for spinal cord compression is allowed. Other limited field radiation involving ? / of the pelvic area is also allowed)
Subjects are allowed to have received radiotherapy before enrollment if radiation was given to alleviate pain and/or neurologic compromise as long as there remains areas of measurable disease present; further, at the investigators discretion and for patients who are unstable, one cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) during the phase I portion of trial and one cycle of an anthracycline based chemotherapy in the phase II portion of the trial is allowed prior to enrollment but no more than one cycle; for purposes of this trial, prednisone or other corticosteroids used for non-lymphomatous conditions will be allowed; in addition, a prior/recent short course (=<  weeks) of steroids for symptom relief of lymphoma-related symptoms will be allowed
Have had radiation within  months of the first dose of AG- or AG-. (Note: Prior biopsy or surgery is allowed.)
IV, intraperitoneal, or neoadjuvant platinum-based chemotherapy is allowed; for weekly therapy,  weeks is considered  cycle. Interval debulking is allowed.
No prior use of EGFR tyrosine kinase inhibitors or monoclonal antibodies; all other prior treatments are allowed if >=  weeks since treatment completed, including chemotherapy (systemic or intraperitoneal), radiation therapy, and/or surgery; there is no limit on the number of previous treatments allowed
No prior bortezomib is allowed
A patient may be treatment nave; however, up to two prior regimens for metastatic melanoma are allowed; prior adjuvant interferon (IFN)-alpha is allowed; no prior therapy with bevacizumab, aflibercept or interleukin- (IL-)
Histologically confirmed stage IV NSCLC (squamous, adenocarcinoma, or large cell carcinoma) that is stable or has partially responded after four cycles of a platinum doublet; (a complete response is not allowed) there is no restriction on prior lines of therapy; maintenance chemotherapy is not allowed
No prior chemotherapy, radiation therapy or immunotherapy for DLBCL; a short course (<  weeks) of corticosteroids is allowed for symptom control
Oral or transdermal estrogen therapy is not allowed
Currently using any other pharmacologic agents or nonpharmacologic interventions to specifically treat fatigue, including psychostimulants, antidepressants, acupuncture, etc. will be excluded; Note: antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for >=  days prior to registration and plans to continue for the duration of the trial; erythropoietin agents to treat anemia are allowed; exercise is allowed
The use of memantine during or following radiation is NOT allowed
Participants are allowed to have received up to  prior lines of chemotherapy in the metastatic setting; if a prior chemotherapy was given for less than  cycle, it will not be counted as a prior line; the last dose of chemotherapy must be =<  days prior to initiation of study therapy; participants should be adequately recovered from acute toxicities of prior treatment; no prior treatment with eribulin mesylate is allowed
Patients with up to two recurrences are allowed.
Subjects unable to discontinue benzodiazepines will not be allowed as hypnotics; additional antiemetics will be allowed for rescue but not for prophylaxis
Prior tamoxifen use is allowed
Prior chemotherapy is allowed
Glucocorticoid use is allowed
Any of the following current (=<  weeks prior) or planned therapies:\r\n* Antineoplastic chemotherapy (anti-HER agents allowed)\r\n* Androgens\r\n* Estrogens (any delivery route)\r\n* Progestogens\r\n* Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least  days and must not be expected to stop the medication during the study period\r\n* Selective serotonin reuptake inhibitors (SSRIs)/serotoninnorepinephrine reuptake inhibitors (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration\r\n* Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration)\r\n* Clonidine\r\n* Agents with known potent anticholinergic activity; agents with mild-moderate anticholinergic activity are allowed
The following patient-related situations are allowed: prior surgery, concurrent treatment, homecare, residing in assisted living or a skilled nursing facility, and hospitalization during radiation therapy
Prior/concurrent radiation allowed
Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy            \r\n* Anthracycline-containing regimens allowed\r\n* Patients receive trastuzumab with their chemotherapy allowed for eligibility work-up\r\n* Taxanes are allowed\r\n* Trastuzumab therapy may be given with or after primary chemotherapy
Prior therapy with hydroxyurea, interferon, anagrelide, ruxolitinib, hypomethylating agents, Revlimid, thalidomide, steroids, other JAK inhibitors is allowed for AML patients who are back in chronic phase MPN, prior induction chemotherapy is allowed
Presence of at least  fallopian tube and  ovary; (please note: prior unilateral salpingectomy is allowed; prior bilateral salpingectomy is not allowed)
Patients with brain metastases are allowed on this study (concurrent treatment with steroids is allowed)
Must agree to use effective consistent contraception. Hormone-based birth control (pills, patches, or shots) is allowed. Hormone replacement therapy is not allowed for postmenopausal participants.
Prior bilateral salpingectomy; prior unilateral salpingectomy is allowed
There are no limits on prior therapy; patients are allowed to have prior systemic therapy, radiation therapy, radiofrequency ablation, catheter-based therapies, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment
Prior therapy is allowed
No recent treatment for thyroid cancer as defined as:\r\n* No prior I therapy is allowed <  months prior to initiation of therapy on this protocol; a diagnostic study using =<  MBq of I is not considered I therapy\r\n* No external beam radiation therapy <  weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)\r\n* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed <  weeks prior to inclusion on this protocol
Any types and amounts of prior therapy will be allowed for this study
Any types and amounts of prior therapy will be allowed for this study
